Combination chemoimmunotherapy with monthly cycles of 5-fluorouracil + interferon-alfa-2b in previously-treated advanced cancer
© Quan et al; licensee BioMed Central Ltd. 2013
Published: 7 November 2013
The in vitro antineoplastic activity of the combination of 5-fluorouracil (5-FU) and interferon-alfa (IFN) has been attributed to multiple mechanisms including enhanced thymidylate synthase inhibition (Elias) and increased susceptibility to interferon-stimulated natural killer cells (Imai). Our group has previously examined weekly dosing schedules of 5-FU and IFN (Quan). Monthly bolus 5-FU + interferon-alfa-2b has not undergone formal phase II testing. In our current study, 18 patients with metastatic cancer who had experienced disease progression on at least 2 prior lines of systemic therapy, have been treated with 5-FU 500 mg/M2 intravenously over 3-5 minutes followed immediately by IFN-2b 3 million IU subcutaneously daily for 3 days monthly on an outpatient basis. Patient characteristics: 12 males/6 females, median age-57 (range: 35-69), median ECOG performance status-1; most common tumor types: colon (6), adenocarcinoma of the lung (4), rectum (3), pancreas (3); common metastatic sites: liver (11), lymph nodes (10), lungs (9). Median number of prior chemotherapy regimens: 3 (range: 2-8). Most common toxicities: rigors, nausea/emesis, fever, and fatigue. Median number of cycles received: 2 (1-11). Sixteen patients are evaluable for response (2 are too early). Two ongoing partial responses have been seen: One patient with adenocarcinoma of the lung (lung + lymph node metastases) at 8.9+ months and one with colon (liver and lymph node metastases at 1.25+ months. Thymidylate synthase levels are being analyzed. Monthly bolus 5-FU followed by subcutaneous IFN-2b is well-tolerated in previously-treated metastatic cancer and shows some evidence of activity in adenocarcinoma of the lung and colon cancer.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.